Moxetumomab pasudotox

Moxetumomab pasudotox is a recombinant immunotoxin used in the treatment of certain types of cancer. It is specifically designed to target and kill cancer cells expressing the CD22 antigen, which is commonly found on the surface of B-cell malignancies.

Mechanism of Action

Moxetumomab pasudotox is composed of an antibody fragment that binds to the CD22 antigen and a toxin derived from Pseudomonas exotoxin A. Upon binding to the CD22 antigen on the surface of cancer cells, the drug is internalized, and the toxin component is released inside the cell. This leads to the inhibition of protein synthesis and ultimately induces apoptosis (programmed cell death) in the targeted cancer cells.

Indications

Moxetumomab pasudotox is primarily indicated for the treatment of hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Administration

The drug is administered via intravenous infusion over a period of 30 minutes. The recommended dosage and treatment schedule are determined based on the patient's body surface area and overall health condition.

Side Effects

Common side effects of moxetumomab pasudotox include:

• Fatigue
• Nausea
• Headache
• Fever
• Edema
• Anemia
• Thrombocytopenia

Serious side effects may include:

• Capillary leak syndrome
• Hemolytic uremic syndrome
• Severe hypersensitivity reactions

Clinical Trials

Moxetumomab pasudotox has undergone several clinical trials to evaluate its efficacy and safety in patients with hairy cell leukemia and other B-cell malignancies. These trials have demonstrated significant clinical activity and manageable toxicity profiles.

Approval

The U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox in September 2018 for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies.

Related Pages

• Immunotoxin
• Hairy cell leukemia
• CD22
• Apoptosis
• Intravenous infusion
• Clinical trials